Table 1.
Summary characteristics of the 22 studies included in meta-analysis
| Characteristics | Summary Data |
|---|---|
|
| |
| Study Characteristics | |
| Year of publication – n (%) | |
| 2004 – 2008 | 2 (9.1) |
| 2009 – 2010 | 3 (13.6) |
| 2011 – 2012 | 8 (36.4) |
| 2013 – 2014 | 9 (40.9) |
| Journal Impact Factor – median (Q1 – Q3) | 2.96 (2.54 – 4.13) |
| Quality Score – median (Q1 – Q3) | 6 (5 – 7) |
| Presence of additional non IV BM MNC arms | 13 (59.1) |
|
| |
| Animal Characteristics | |
|
| |
| Animal Type – n (%) | |
| Rats | 20 (90.9) |
| Mice | 2 (9.1) |
| Animal Species / Type – n (%) | |
| Rats (n = 20) | |
| Wistar | 8 (40.0) |
| Sprague-Dawley | 6 (30.0) |
| Long Evans | 3 (15.0) |
| SHR* / SHR – SP† | 3 (15.0) |
| Mice (n = 2) | |
| SCID‡ | 1 (50.0) |
| BALB / c§ | 1 (50.0) |
| Animal Gender – n (%) | |
| Male | 19 (86.4) |
| Female | 1 (4.6) |
| Both | 1 (4.6) |
| Not specified | 1 (4.6) |
| Animal Weight Categories – n (%) | |
| 18 – 20 gr | 1 (4.6) |
| 220 – 450 gr | 15 (68.2) |
| 600 – 800 gr | 1 (4.6) |
| Not specified | 5 (22.7) |
|
| |
| Cell Characteristics | |
|
| |
| Cell source – n (%) | |
| Allogeneic | 14 (63.3) |
| Autologous | 7 (31.8) |
| Human | 1 (4.6) |
| Bone Marrow Harvest (autologous cell source) – n (%) | |
| After experimental stroke | 5 (71.4) |
| Before experimental stroke | 2 (28.5) |
| Cell Dose (n = 24, more than 1 experiment / study included) | |
| 30 million cells | 7 (29.2) |
| 20 million cells | 1 (4.2) |
| 10 million cells | 8 (33.3) |
| 8 million cells | 1 (4.2) |
| 5 million cells | 3 (12.5) |
| 3 million cells | 1 (4.2) |
| 1 million cells | 3 (12.5) |
| Timing (n = 37, more than 1 experiment / study included) | |
| ≤ 12 hours | 11 (29.7) |
| 24 hours | 17 (45.9) |
| 48 hours | 2 (5.4) |
| 72 hours | 3 (8.1) |
| > 72 hours | 4 (10.8) |
| Site of delivery - n (%) | |
| Femoral Vein | 7 (31.8) |
| Tail Vein | 7 (31.8) |
| Jugular | 5 (22.7) |
| Not specified | 3 (13.6) |
|
| |
| Stroke type Characteristics | |
|
| |
| Mechanism of ischemia - n (%) | |
| MCAO∥ - Intraluminal Occlusion | 8 (36.4) |
| MCAO - Coagulation / Ligation | 6 (27.3) |
| Thermocoagulation | 5 (22.7) |
| Vasoconstrictor Peptide | 2 (9.1) |
| Cortical Ablation | 1 (4.6) |
| Type of ischemia - n (%) | |
| Permanent | 14 (63.6) |
| Transient | 8 (36.4) |
| Duration of transient ischemia (n = 8) | |
| 180 minutes | 2 (25.0) |
| 90 minutes | 4 (50.0) |
| 60 minutes | 1 (12.5) |
| 45 minutes | 1 (12.5) |
*
SHR: Spontaneously Hypertensive Rats.
†
SHR - SP: Spontaneously Hypertensive Rats -Stroke Prone.
‡
SCID: Severe combined immunodeficiency.
§
BALB/c: Bagg Albino (inbred research mouse strain).
∥
MCAO: Middle Cerebral Artery Occlusion